Uncertainty surrounds the benefit of preventive pharmacological therapies in reducing aortic disease in patients with Marfan syndrome. The Marfan Sartan trial now suggests that losartan is not beneficial in reducing the rate of aortic dilatation—the precursor of dissections and premature death in Marfan syndrome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Milleron, O. et al. Marfan Sartan: a randomized, double-blind, placebo-controlled trial. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehv151.
Hartog, A. W., Franken, R., Zwinderman, A. H., Groenink, M. & Mulder, B. J. Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome. Expert Opin. Pharmacother. 13, 647–662 (2012).
Franken, R. et al. Circulating transforming growth factor-β as a prognostic biomarker in Marfan syndrome. Int. J. Cardiol. 168, 2441–2446 (2013).
Brooke, S. B. et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Engl. J. Med. 358, 2787–2795 (2008).
Chiu, H. H. et al. Losartan added to β-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin. Proc. 88, 271–276 (2013).
Groenink, M. et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: an open-label randomized clinical trial. Eur. Heart J. 34, 3491–3500 (2013).
Franken, R. et al. Beneficial outcome of losartan therapy depends on type of FBN1 mutation in Marfan syndrome. Circ. Cardiovasc. Genet. 8, 383–388 (2015).
Lacro, R. V. et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N. Engl. J. Med. 371, 2061–2071 (2014).
Pitcher, A. et al. Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: a report from the Marfan Treatment Trialists' Collaboration. Am. Heart J. 169, 605–612 (2015).
Acknowledgements
R.F. is funded by a fellowship grant from the Interuniversity Cardiology Institute of the Netherlands.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Franken, R., Mulder, B. Losartan versus atenolol in the Marfan aorta—how to treat?. Nat Rev Cardiol 12, 447–448 (2015). https://doi.org/10.1038/nrcardio.2015.95
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2015.95
This article is cited by
-
Vascular smooth muscle cells in Marfan syndrome aneurysm: the broken bricks in the aortic wall
Cellular and Molecular Life Sciences (2017)
-
Aortenbogenchirurgie – eine Übersicht
Gefässchirurgie (2016)
-
Aortenbogenchirurgie
Zeitschrift für Herz-,Thorax- und Gefäßchirurgie (2016)
